Financial Instruments and Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended																							9 Months Ended
	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013	Jun. 29, 2012	Jun. 28, 2013 Spain and Italy	Jun. 29, 2012 Spain and Italy	Jun. 28, 2013 Spain and Italy	Jun. 29, 2012 Spain and Italy	Jun. 28, 2013 CNS Therapeutics, Inc.	Oct. 01, 2012 CNS Therapeutics, Inc.	Jun. 28, 2013 Debentures 7.00% Debenture	Jun. 28, 2013 Debentures 7.00% Debenture Level 2		Jun. 28, 2013 Debentures 8.00% Debenture	Jun. 28, 2013 Debentures 8.00% Debenture Level 2		Jun. 28, 2013 Debentures 9.50% Debenture	Jun. 28, 2013 Debentures 9.50% Debenture Level 2		Apr. 30, 2013 Senior Notes 3.50% Senior Note	Jun. 28, 2013 Senior Notes 3.50% Senior Note Level 1		Apr. 30, 2013 Senior Notes 4.75% Senior Note	Jun. 28, 2013 Senior Notes 4.75% Senior Note Level 1		Jun. 28, 2013 Carrying Value Level 1	Sep. 28, 2012 Carrying Value Level 1	Jun. 28, 2013 Carrying Value Level 3	Sep. 28, 2012 Carrying Value Level 3	Jun. 28, 2013 Recurring Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in fair value of investments																														$ 10,400,000
Fair value of contingent consideration upon acquisition										6,900,000
Maximum contingent payments for acquisition										9,000,000
Discount rate									1.00%
Restricted cash and cash equivalents																										23,900,000	24,600,000
Cash surrender value of life insurance																												66,500,000	47,600,000
Increase (decrease) in cash surrender value of life insurance contracts			18,900,000
Stated interest rate											7.00%	7.00%	[1]	8.00%	8.00%	[1]	9.50%	9.50%	[1]	3.50%	3.50%	[1]	4.75%	4.75%	[1]
Net sales	$ 570,000,000	$ 516,300,000	$ 1,659,300,000	$ 1,543,100,000	$ 13,400,000	$ 14,000,000	$ 39,700,000	$ 43,000,000

[1] Under the terms of the separation and distribution agreement entered into with Covidien on June 28, 2013, the 7.00% debentures due December 2013 were retained by Covidien.